Radiation Therapy Oncology Group (RTOG) Altered Fractionation Trials

The Radiation Therapy Oncology Group (RTOG) has been conducting clinical trials of altered fractionation radiotherapy since 1977. Altered fractionation schemes tested include hyperfractionation, several types of accelerated fractionation as well as hypofractionation. Initial trials were aimed at establishing the maximum tolerable dose using altered fractionation in various disease sites including head and neck, lung, brain, pelvis, and the gastrointestinal tract. Results of Phase I/U studies of hyperfraetionated radiotherapy clearly demonstrated that escalation of total doses to 15- 20% higher than those used in conventional fractionation can be achieved with acceptable acute toxicity and no significant increase of late toxicity. A dose-response relationship for tumor control was observed in head and neck cancer, non-small cell lung cancer and malignant gliomas. Daily interfraction interval ＜ 4.5 h was a significant risk factor for acute toxicity and late effects. Treatment interruption ＞ 5 days was detrimental to tumor control and survival. These studies have identified appropriate doses using hyperfractionation for comparison with standard fractionation, accelerated fractionation and other experimental treatments for the different disease sites. Phase III comparisons of hyperfractionation versus standard fractionation with or without chemotherapy have been completed in non-small cell lung cancer and malignant gliomas. For non-small cell lung cancer, induction chemotherapy followed by standard fractionated radiotherapy yielded better survival than hyperfractionated or standard fractionated radiotherapy alone. A Phase JIJ trial comparing hyperfractionation and BCNU to standard fractionation and I3CNU for malignant gliomas has completed patient accrual; results are not available yet. A Phase III comparison of standard fractionation and hyperfractionation and two variants of accelerated fractionation for head and neck cancer is in progress.

並列關鍵字

Altered fractionation radiotherapy ； Hyperfractionation ； Accelerated fractionation ； Hypofractionation ； Clinical trials ； RTOG

被引用紀錄

Chao, C. C. (2009). 安身立命於無以為（國）家：泰緬邊境克倫難民的民族主義 [doctoral dissertation, National Taiwan University]. Airiti Library. https://doi.org/10.6342/NTU.2009.01801

羅玉珠（2011）。外在社會控制、內在價值信仰與兒童偏差行為相關性之研究〔碩士論文，國立臺北大學〕。華藝線上圖書館。https://www.airitilibrary.com/Article/Detail?DocID=U0023-0607201114012000

延伸閱讀

Chen, J. L. Y. (2018). Radiosensitizer in Cancer Radiation Therapy [doctoral dissertation, National Taiwan University]. Airiti Library. https://doi.org/10.6342/NTU201800095
Kuo, Y. T., Chern, Y. J., Lin, Y. C., Hsu, Y. J., Tsai, W. S., Hsieh, P. S., Hung, H. Y., Yeh, C. Y., Chiang, S. F., Lai, C. C., You, J. F., Tang, R. P., Chen, J. S., Chiang, J. M., & Liao, C. K. (2021). Short-course Radiation Therapy Followed by Chemotherapy as Preoperative Treatment for Rectal Cancer. 中華民國大腸直腸外科醫學會雜誌, 32(1), 7-16. https://doi.org/10.6312/SCRSTW.202103_32(1).10920
Jain, A. K., & Ennis, R. D. (2012). Focal Therapy, Differential Therapy, and Radiation Treatment for Prostate Cancer. Advances in Urology, 2012(), 425-430. https://doi.org/10.1155/2012/573193
Liou, C. H., Liu, M. T., Chang, T. H., Pi, C. P., Wang, A. Y., Liu, W. S., Huang, C. Y., Wang, A. Y., Liu, W. S., & Huang2, C. Y. (2006). Radiation therapy with or without hormonal therapy for prostate carcinomafor prostate carcinoma. 放射治療與腫瘤學, 13(3), 175-183. https://doi.org/10.6316/TRO/200613(3)175
蘇志中、顏上惠、吳錦榕、許文林、林光大（1988）。Radiation Therapy of Brain Stem Tumors。中華放射線醫學雜誌，13(3)，313-319。https://www.airitilibrary.com/Article/Detail?DocID=10188940-198809-13-3-313-319-a

國際替代計量

Radiation Therapy Oncology Group (RTOG) Altered Fractionation Trials

全文下載

主題瀏覽